Recombinant Newcastle Disease Virus-Vectored Vaccines Against Human and Animal Infectious Diseases

References

• Ada G . Overview of vaccines and vaccination . Mol. Biotechnol.29 ( 3 ), 255 – 272 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• De Groot AS , EinckL , MoiseLet al. Making vaccines ’on demand’: a potential solution for emerging pathogens and biodefense? Hum. Vaccin. Immunother. 9 ( 9 ), 1877 – 1884 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ngcobo NJ , CameronNA . The decision making process on new vaccines introduction in South Africa . Vaccine30 ( Suppl. 3 ), C9 – C13 ( 2012 ).
   PubMedGoogle Scholar
• Gruters R , OsterhausA . AIDS vaccine research: consider co-infections . Science319 ( 5868 ), 1337 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ulbert S , MagnussonSE . Technologies for the development of West Nile virus vaccines . Future Microbiol.9 ( 10 ), 1221 – 1232 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Deen JL , ClemensJD . Issues in the design and implementation of vaccine trials in less developed countries . Nat. Rev. Drug. Discov.5 ( 11 ), 932 – 940 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Alemayehu D , UttE , KnirschC . Vaccines: a review of immune-based interventions to prevent and treat disease . J. Clin. Pharmacol.55 ( Suppl. 3 ), S93 – S102 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hoft DF , BrusicV , SakalaIG . Optimizing vaccine development . Cell. Microbiol.13 ( 7 ), 934 – 942 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE . Research highlights: highlights from the latest articles in optimizing vaccine development . Immunotherapy4 ( 5 ), 469 – 471 ( 2012 ).
   PubMedGoogle Scholar
• Gregersen JP . DNA vaccines . Naturwissenschaften88 ( 12 ), 504 – 513 ( 2001 ).
   PubMedGoogle Scholar
• Souza AP , HautL , Reyes-SandovalA , PintoAR . Recombinant viruses as vaccines against viral diseases . Braz. J. Med. Biol. Res.38 ( 4 ), 509 – 522 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Tripp RA , TompkinsSM . Virus-vectored influenza virus vaccines . Viruses6 ( 8 ), 3055 – 3079 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Schnepp BC , JohnsonPR . Vector-mediated antibody gene transfer for infectious diseases . Adv. Exp. Med. Biol.848 , 149 – 167 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Xiao S , KumarM , YangXet al. A host-restricted viral vector for antigen-specific immunization against lyme disease pathogen . Vaccine29 ( 32 ), 5294 – 5303 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ganar K , DasM , SinhaS , KumarS . Newcastle disease virus: current status and our understanding . Virus Res.184 , 71 – 81 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Nakaya T , CrosJ , ParkMSet al. Recombinant Newcastle disease virus as a vaccine vector . J. Virol.75 ( 23 ), 11868 – 11873 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Bukreyev A , CollinsPL . Newcastle disease virus as a vaccine vector for humans . Curr. Opin. Mol. Ther.10 ( 1 ), 46 – 55 ( 2008 ).
   PubMedGoogle Scholar
• Huang Z , ElankumaranS , PandaA , SamalSK . Recombinant Newcastle disease virus as a vaccine vector . Poult Sci.82 ( 6 ), 899 – 906 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V , FournierP . Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer . Methods Mol. Biol.542 , 565 – 605 ( 2009 ).
   PubMedGoogle Scholar
• Miller PJ , DecaniniEL , AfonsoCL . Newcastle disease: evolution of genotypes and the related diagnostic challenges . Infect. Genet. Evol.10 ( 1 ), 26 – 35 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Mayo MA . A summary of taxonomic changes recently approved by ICTV . Arch. Virol.147 ( 8 ), 1655 – 1663 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Kattenbelt JA , StevensMP , GouldAR . Sequence variation in the Newcastle disease virus genome . Virus Res.116 ( 1–2 ), 168 – 184 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Yusoff K , TanWS . Newcastle disease virus: macromolecules and opportunities . Avian Pathol.30 ( 5 ), 439 – 455 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Hamaguchi M , YoshidaT , NishikawaK , NaruseH , NagaiY . Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex . Virology128 ( 1 ), 105 – 117 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Hamaguchi M , NishikawaK , ToyodaT , YoshidaT , HanaichiT , NagaiY . Transcriptive complex of Newcastle disease virus. II. Structural and functional assembly associated with the cytoskeletal framework . Virology147 ( 2 ), 295 – 308 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Pantua HD , McginnesLW , PeeplesME , MorrisonTG . Requirements for the assembly and release of Newcastle disease virus-like particles . J. Virol.80 ( 22 ), 11062 – 11073 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Duan Z , HuZ , ZhuJet al. Mutations in the FPIV motif of Newcastle disease virus matrix protein attenuate virus replication and reduce virus budding . Arch. Virol.159 ( 7 ), 1813 – 1819 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Smith EC , PopaA , ChangA , MasanteC , DutchRE . Viral entry mechanisms: the increasing diversity of paramyxovirus entry . FEBS J.276 ( 24 ), 7217 – 7227 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kurilla MG , StoneHO , KeeneJD . RNA sequence and transcriptional properties of the 3’ end of the Newcastle disease virus genome . Virology145 ( 2 ), 203 – 212 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S , SamalSK . Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence . J. Gen. Virol.79 ( 10 ), 2419 – 2424 ( 1998 ).
   PubMedGoogle Scholar
• Walpita P , FlickR . Reverse genetics of negative-stranded RNA viruses: a global perspective . FEMS Microbiol. Lett.244 ( 1 ), 9 – 18 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Neumann G , WhittMA , KawaokaY . A decade after the generation of a negative-sense RNA virus from cloned cDNA – what have we learned?J. Gen. Virol.83 ( 11 ), 2635 – 2662 ( 2002 ).
   PubMedGoogle Scholar
• Neumann G , KawaokaY . Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA . Curr. Top. Microbiol. Immunol.283 , 43 – 60 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Romer-Oberdorfer A , MundtE , MebatsionT , BuchholzUJ , MettenleiterTC . Generation of recombinant lentogenic Newcastle disease virus from cDNA . J. Gen. Virol.80 ( 11 ), 2987 – 2995 ( 1999 ).
   PubMedGoogle Scholar
• Peeters BP , De LeeuwOS , KochG , GielkensAL . Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence . J. Virol.73 ( 6 ), 5001 – 5009 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S , HuangZ , SamalSK . Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation . Virology278 ( 1 ), 168 – 182 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• De Leeuw OS , KochG , HartogL , RavenshorstN , PeetersBP . Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein . J. Gen. Virol.86 ( Pt 6 ), 1759 – 1769 ( 2005 ).
   PubMedGoogle Scholar
• Liu YL , HuSL , ZhangYMet al. Generation of a velogenic Newcastle disease virus from cDNA and expression of the green fluorescent protein . Arch. Virol.152 ( 7 ), 1241 – 1249 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hu Z , HuS , MengC , WangX , ZhuJ , LiuX . Generation of a genotype VII Newcastle disease virus vaccine candidate with high yield in embryonated chicken eggs . Avian Dis.55 ( 3 ), 391 – 397 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Schnell MJ , MebatsionT , ConzelmannKK . Infectious rabies viruses from cloned cDNA . EMBO J.13 ( 18 ), 4195 – 4203 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Fuerst TR , NilesEG , StudierFW , MossB . Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase . Proc. Natl Acad. Sci. USA83 ( 21 ), 8122 – 8126 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Buchholz UJ , FinkeS , ConzelmannKK . Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter . J. Virol.73 ( 1 ), 251 – 259 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Li BY , LiXR , LanXet al. Rescue of Newcastle disease virus from cloned cDNA using an RNA polymerase II promoter . Arch. Virol.156 ( 6 ), 979 – 986 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Zhang X , LiuH , LiuP , PeetersBP , ZhaoC , KongX . Recovery of avirulent, thermostable Newcastle disease virus strain NDV4-C from cloned cDNA and stable expression of an inserted foreign gene . Arch. Virol.158 ( 10 ), 2115 – 2120 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wang J , WangC , FengNet al. Development of a reverse genetics system based on RNA polymerase II for Newcastle disease virus genotype VII . Virus Genes50 ( 1 ), 152 – 155 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Le Mercier P , JacobY , TannerK , TordoN . A novel expression cassette of lyssavirus shows that the distantly related mokola virus can rescue a defective rabies virus genome . J. Virol.76 ( 4 ), 2024 – 2027 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Inoue K , ShojiY , KuraneI , IijimaT , SakaiT , MorimotoK . An improved method for recovering rabies virus from cloned cDNA . J. Virol. Methods107 ( 2 ), 229 – 236 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Miller PJ , KingDJ , AfonsoCL , SuarezDL . Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge . Vaccine25 ( 41 ), 7238 – 7246 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hu S , MaH , WuYet al. A vaccine candidate of attenuated genotype VII Newcastle disease virus generated by reverse genetics . Vaccine27 ( 6 ), 904 – 910 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Xiao S , NayakB , SamuelAet al. Generation by reverse genetics of an effective, stable, live-attenuated Newcastle disease virus vaccine based on a currently circulating, highly virulent indonesian strain . PLoS ONE7 ( 12 ), e52751 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Liu MM , ChengJL , YuXH , QinZM , TianFL , ZhangGZ . Generation by reverse genetics of an effective attenuated Newcastle disease virus vaccine based on a prevalent highly virulent Chinese strain . Biotechnol. Lett.37 ( 6 ), 1287 – 1296 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wang J , CongY , YinRet al. Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of goose parvovirus as a bivalent vaccine in goslings . Virus Res.203 , 77 – 83 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Peeters BP , De LeeuwOS , VerstegenI , KochG , GielkensAL . Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals . Vaccine19 ( 13–14 ), 1616 – 1627 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Vigil A , ParkMS , MartinezOet al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus . Cancer Res.67 ( 17 ), 8285 – 8292 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Kim SH , PalduraiA , XiaoS , CollinsPL , SamalSK . Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens . Vaccine32 ( 35 ), 4428 – 4435 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kim SH , SubbiahM , SamuelAS , CollinsPL , SamalSK . Roles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxoviruses . J. Virol.85 ( 17 ), 8582 – 8596 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Nayak B , DiasFM , KumarS , PalduraiA , CollinsPL , SamalSK . Avian paramyxovirus serotypes 2–9 (APMV-2–9) vary in the ability to induce protective immunity in chickens against challenge with virulent Newcastle disease virus (APMV-1) . Vaccine30 ( 12 ), 2220 – 2227 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Samuel AS , SubbiahM , ShiveH , CollinsPL , SamalSK . Experimental infection of hamsters with avian paramyxovirus serotypes 1 to 9 . Vet. Res.42 , 38 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Grund C , SteglichC , HuthmannE , BeerM , MettenleiterTC , Romer-OberdorferA . Avian paramyoxvirus-8 immunization reduces viral shedding after homologous APMV-8 challenge but fails to protect against Newcastle disease . Virol. J.11 , 179 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Steglich C , GrundC , RampKet al. Chimeric Newcastle disease virus protects chickens against avian influenza in the presence of maternally derived NDV immunity . PLoS ONE8 ( 9 ), e72530 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Nagai Y . Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding . Rev. Med. Virol.9 ( 2 ), 83 – 99 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Zhao H , PeetersBP . Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication . J. Gen. Virol.84 ( 4 ), 781 – 788 ( 2003 ).
   PubMedGoogle Scholar
• Bukreyev A , HuangZ , YangLet al. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates . J. Virol.79 ( 21 ), 13275 – 13284 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Huang Z , KrishnamurthyS , PandaA , SamalSK . High-level expression of a foreign gene from the most 3′-proximal locus of a recombinant Newcastle disease virus . J. Gen. Virol.82 ( Pt 7 ), 1729 – 1736 ( 2001 ).
   PubMedGoogle Scholar
• He B , PatersonRG , WardCD , LambRA . Recovery of infectious SV5 from cloned DNA and expression of a foreign gene . Virology237 ( 2 ), 249 – 260 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Yan Y , SamalSK . Role of intergenic sequences in Newcastle disease virus RNA transcription and pathogenesis . J. Virol.82 ( 3 ), 1323 – 1331 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Zhao W , ZhangZ , ZsakL , YuQ . P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression . J. Gen. Virol.96 ( 1 ), 40 – 45 ( 2015 ).
   PubMedGoogle Scholar
• Wen G , ChenC , GuoJet al. Development of a novel thermostable Newcastle disease virus vaccine vector for expression of a heterologous gene . J. Gen. Virol.96 , 1219 – 1228 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Susta L , CornaxI , DielDGet al. Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens . Microb. Pathog.61 – 62 , 73 – 83 ( 2013 ).
   Web of Science ®Google Scholar
• Zhao L , MeiY , SunQet al. Autologous tumor vaccine modified with recombinant Newcastle disease virus expressing IL-7 promotes antitumor immune response . J. Immunol.193 ( 2 ), 735 – 745 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bukreyev A , SkiadopoulosMH , MurphyBR , CollinsPL . Nonsegmented negative-strand viruses as vaccine vectors . J. Virol.80 ( 21 ), 10293 – 10306 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Chare ER , GouldEA , HolmesEC . Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses . J. Gen. Virol.84 ( Pt 10 ), 2691 – 2703 ( 2003 ).
   PubMedGoogle Scholar
• Song Q , CaoY , LiQet al. Artificial recombination may influence the evolutionary analysis of Newcastle disease virus . J. Virol.85 ( 19 ), 10409 – 10414 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Shrivastava SR , ShrivastavaPS , RamasamyJ . Emerging and re-emerging infectious diseases: public health perspective . Int. J. Prev. Med.4 ( 6 ), 736 – 737 ( 2013 ).
   PubMedGoogle Scholar
• Stramer SL . Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections . ISBT Sci. Ser.9 ( 1 ), 30 – 36 ( 2014 ).
   PubMedGoogle Scholar
• Sato H , YonedaM , HondaT , KaiC . Recombinant vaccines against the mononegaviruses-what we have learned from animal disease controls . Virus Res.162 ( 1–2 ), 63 – 71 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Cassel WA , GarrettRE . Newcastle disease virus as an antineoplastic agent . Cancer18 , 863 – 868 ( 1965 ).
   PubMed Web of Science ®Google Scholar
• Stojdl DF , LichtyB , KnowlesSet al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus . Nat. Med.6 ( 7 ), 821 – 825 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V , GriesbachA , AhlertT . Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects . Int. J. Oncol.18 ( 5 ), 945 – 952 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Schulze T , KemmnerW , WeitzJ , WerneckeKD , SchirrmacherV , SchlagPM . Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial . Cancer Immunol. Immunother.58 ( 1 ), 61 – 69 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lam HY , YeapSK , RasoliMet al. Safety and clinical usage of Newcastle disease virus in cancer therapy . J. Biomed. Biotechnol.2011 , 718710 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Shobana R , SamalSK , ElankumaranS . Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy . J. Virol.87 ( 7 ), 3792 – 3800 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sun Y , ZhangY , ShiCet al. Newcastle disease virus vaccine encapsulated in biodegradable nanoparticles for mucosal delivery of a human vaccine . Hum. Vaccin. Immunother.10 ( 8 ), 2503 – 2506 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jafa K , McelroyP , FitzpatrickLet al. HIV transmission in a state prison system, 1988–2005 . PLoS ONE4 ( 5 ), e5416 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Nickle DC , JensenMA , GottliebGSet al. Consensus and ancestral state HIV vaccines . Science299 ( 5612 ), 1515 – 1518 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Nakaya Y , ZhengH , Garcia-SastreA . Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants . Vaccine21 ( 17–18 ), 2097 – 2106 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Piantadosi A , ChohanB , PanteleeffDet al. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response . AIDS23 ( 5 ), 579 – 587 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Nakaya Y , NakayaT , ParkMSet al. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors . J. Virol.78 ( 17 ), 9366 – 9375 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Carnero E , LiW , BorderiaAV , MoltedoB , MoranT , Garcia-SastreA . Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses . J. Virol.83 ( 2 ), 584 – 597 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Khattar SK , SamalS , DevicoAL , CollinsPL , SamalSK . Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in guinea pigs . J. Virol.85 ( 20 ), 10529 – 10541 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Khattar SK , SamalS , LabrancheCC , MontefioriDC , CollinsPL , SamalSK . Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated Newcastle disease virus vector . PLoS ONE8 ( 10 ), e78521 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Khattar SK , PalaniyandiSK , SamalSet al. Evaluation of humoral, mucosal and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus . Hum. Vaccin. Immunother.11 ( 2 ), 504 – 515 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Dinapoli JM , KotelkinA , YangLet al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens . Proc. Natl Acad. Sci. USA104 ( 23 ), 9788 – 9793 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Gimm G , NicholsLM . Ebola crisis of 2014: are current strategies enough to meet the long-run challenges ahead?Am. J. Public Health10 ( 5 ), e8 – e10 ( 2015 ).
   Google Scholar
• Dinapoli JM , YangL , SamalSK , MurphyBR , CollinsPL , BukreyevA . Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response . Vaccine29 ( 1 ), 17 – 25 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sivasamugham LA , CardosaMJ , TanWS , YusoffK . Recombinant Newcastle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits . J. Med. Virol.78 ( 8 ), 1096 – 1104 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Martinez-Sobrido L , GitibanN , Fernandez-SesmaAet al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector . J. Virol.80 ( 3 ), 1130 – 1139 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kong D , WenZ , SuHet al. Newcastle disease virus-vectored nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs . Virology432 ( 2 ), 327 – 335 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kortekaas J , De BoerSM , KantJ , VloetRP , AntonisAF , MoormannRJ . Rift valley fever virus immunity provided by a paramyxovirus vaccine vector . Vaccine28 ( 27 ), 4394 – 4401 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kim SH , ChenS , JiangX , GreenKY , SamalSK . Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice . J. Virol.88 ( 17 ), 9718 – 9727 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gebreyes WA , Dupouy-CametJ , NewportMJet al. The global one health paradigm: challenges and opportunities for tackling infectious diseases at the human, animal, and environment interface in low-resource settings . PLoS Negl. Trop. Dis.8 ( 11 ), e3257 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• England JJ . Animal health emergency diseases. Introduction . Vet. Clin. North Am. Food. Anim. Pract.18 ( 3 ), xi – xii ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Schmaljohn C , MandlCW . The interface of animal and human vaccines . Curr. Opin. Virol.2 ( 3 ), 306 – 308 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Blaxland JD . Vaccines in the prevention and control of avian virus diseases . Veterinarian3 , 79 – 86 ( 1965 ).
   PubMedGoogle Scholar
• Swayne DE . Vaccines for list a poultry diseases: emphasis on avian influenza . Dev. Biol. (Basel)114 , 201 – 212 ( 2003 ).
   PubMedGoogle Scholar
• Roche SE , CoggerN , GarnerMG , PutraAA , ToribioJA . Assessing the risk of highly pathogenic avian influenza H5N1 transmission through poultry movements in Bali, Indonesia . Prev. Vet. Med.113 ( 4 ), 599 – 607 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hoper D , KalthoffD , HoffmannB , BeerM . Highly pathogenic avian influenza virus subtype H5N1 escaping neutralization: more than HA variation . J. Virol.86 ( 3 ), 1394 – 1404 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Spackman E , SwayneDE , Pantin-JackwoodMJet al. Variation in protection of four divergent avian influenza virus vaccine seed strains against eight clade 2.2.1 and 2.2.1.1. Egyptian H5N1 high pathogenicity variants in poultry . Influenza Other Respir. Viruses8 ( 6 ), 654 – 662 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pappaioanou M . Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic?Comp. Immunol. Microbiol. Infect. Dis.32 ( 4 ), 287 – 300 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Veits J , WiesnerD , FuchsWet al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza . Proc. Natl Acad. Sci. USA103 ( 21 ), 8197 – 8202 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ge J , DengG , WenZet al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses . J. Virol.81 ( 1 ), 150 – 158 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Dinapoli JM , YangL , SuguitanAJret al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus . J. Virol.81 ( 21 ), 11560 – 11568 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Romer-Oberdorfer A , VeitsJ , HelferichD , MettenleiterTC . Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus . Vaccine26 ( 19 ), 2307 – 2313 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Dinapoli JM , NayakB , YangLet al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys . J. Virol.84 ( 3 ), 1489 – 1503 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ferreira HL , PirlotJF , ReynardF , Van Den BergT , BublotM , LambrechtB . Immune responses and protection against H5N1 highly pathogenic avian influenza virus induced by the Newcastle disease virus H5 vaccine in ducks . Avian Dis.56 ( 4 ), 940 – 948 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Swayne DE , SuarezDL , Schultz-CherrySet al. Recombinant paramyxovirus type 1-avian influenza-H7 virus as a vaccine for protection of chickens against influenza and Newcastle disease . Avian Dis.47 ( 3 ), 1047 – 1050 ( 2003 ).
   PubMedGoogle Scholar
• Schroer D , VeitsJ , GrundCet al. Vaccination with Newcastle disease virus vectored vaccine protects chickens against highly pathogenic H7 avian influenza virus . Avian Dis.53 ( 2 ), 190 – 197 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Smith J , SadeyenJR , ButterC , KaiserP , BurtDW . Analysis of the early immune response to infection by infectious bursal disease virus in chickens differing in their resistance to the disease . J. Virol.89 ( 5 ), 2469 – 2482 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gao L , QiX , LiKet al. Development of a tailored vaccine against challenge with very virulent infectious bursal disease virus of chickens using reverse genetics . Vaccine29 ( 33 ), 5550 – 5557 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Huang Z , ElankumaranS , YunusAS , SamalSK . A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV . J. Virol.78 ( 18 ), 10054 – 10063 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Kanabagatte Basavarajappa M , KumarS , KhattarSK , GebreluulGT , PalduraiA , SamalSK . A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein d protects against highly virulent ILTV and NDV challenges in chickens . Vaccine32 ( 28 ), 3555 – 3563 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhao W , SpatzS , ZhangZet al. Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges . J. Virol.88 ( 15 ), 8397 – 8406 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Khattar SK , CollinsPL , SamalSK . Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1 . Vaccine28 ( 18 ), 3159 – 3170 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ge J , WangX , TaoLet al. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats . J. Virol.85 ( 16 ), 8241 – 8252 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chen H , BuZ . Development and application of avian influenza vaccines in China . Curr. Top. Microbiol. Immunol.333 , 153 – 162 ( 2009 ).
   PubMedGoogle Scholar
• Kortekaas J , DekkerA , De BoerSMet al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus . Vaccine28 ( 11 ), 2271 – 2276 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Dinapoli JM , WardJM , ChengLet al. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans . Vaccine27 ( 10 ), 1530 – 1539 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Mathew A , TownsleyE , EnnisFA . Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections . Future Microbiol.9 ( 3 ), 411 – 425 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Centlivre M , CombadiereB . New challenges in modern vaccinology . BMC Immunol.16 , 18 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zhao K , ChenG , ShiXMet al. Preparation and efficacy of a live Newcastle disease virus vaccine encapsulated in chitosan nanoparticles . PLoS ONE7 ( 12 ), e53314 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhao K , LiW , HuangTet al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles . PLoS ONE8 ( 12 ), e82648 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sun Y , ZhangY , ShiCet al. Newcastle disease virus vaccine encapsulated in biodegradable nanoparticles for mucosal delivery of a human vaccine . Hum. Vaccin. Immunother.10 ( 8 ), 2503 – 2506 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhao K , ZhangY , ZhangXet al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles . Int. J. Nanomedicine9 , 389 – 402 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lawrence TM , WanjallaCN , GommeEAet al. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative-stranded RNA viruses . PLoS ONE8 ( 6 ), e67123 ( 2013 ).
   PubMed Web of Science ®Google Scholar